Small molecule anti-malarial patents: A review (January 2010 June 2011)

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 6, 2012, Pages 607-643

  Svennas, Katarina L ^a   MacDonald, Simon J F ^a   Willis, Paul A ^a  

^a ICC   (Switzerland)

Author keywords

Chemotype; Malaria; Medicines for Malaria Venture; Open innovation; P. falciparum; P. vivax; Plasmodium; Small molecule; Transmission blocking

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISININ; ARTEROLANE; ATOVAQUONE; AZITHROMYCIN; BENFLUMETOL; CHLOROQUINE; FINGOLIMOD; FOSMIDOMYCIN; HEMOGLOBIN; HISTONE DEACETYLASE INHIBITOR; ISOPRENOID; KETOTIFEN; MEFLOQUINE; OZ 439; PLASMEPSIN INHIBITOR; PRIMAQUINE; PROGUANIL; PURINE DERIVATIVE; PYRIMETHAMINE; QUININE; SIRTUIN 1; SOLITHROMYCIN; SPINOSAD; TAFENOQUINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WR 308245; WR 308396;

DISEASE CONTROL; ERADICATION THERAPY; HUMAN; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; NONHUMAN; PARASITE TRANSMISSION; PATENT; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMODIUM FALCIPARUM; REVIEW; SINGLE DRUG DOSE;

ANIMALS; ANTIMALARIALS; DRUG DESIGN; HUMANS; MALARIA; MOLECULAR STRUCTURE; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 84862286881     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.691967     Document Type: Review

References (116)

1. World malaria report, 2010, WHO.Available from: http://www.who.int/ malaria/world-malaria-report-2010/en/ index.html
2. Wells TNC, Alonso PL, Gutteridge WE.New medicines to improve control and contribute to the eradication of malaria.Nat Drug Discov Rev 2009;8:879-91
3. Available from: http://www.reuters.com/ article/2011/01/14/us-malaria- vaccinegsk- idUSTRE70D25L20110114
4. Alonso PL, Brown G, Arevalo-Herrera M, et al.2011 A research agenda to underpin malaria eradication.PLoS Med 2011;8(1):e1000406
5. Available from: http://www.mmv.org/ research-development/science- portfolio 6.Available from: 2010
6. Plouffe D, Brinker A, McNamara C, et al.In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proc Natl Acad Sci USA 2008;105:9059-64
7. Guiguemd WA, Shelat AA, Bouck D., et al.Chemical genetics of Plasmodium falciparum.Nature 2010;465:311-15
8. Gamo F-J, Sanz LM, Vidal J., et al.Thousands of chemical starting points for antimalarial lead identification.Nature 2010;465:305-10
9. Posner GH.D'Angelo J, O'Neill PM, Mercer A.Anticancer activity of artemisinin-derived trioxanes.Expert Opin Ther Patents 2006;12:1665-72
10. Mital A.Recent advances in antimalarial compounds and their patents.Curr Med Chem 2007;14:759-73
11. Monzote L.A review of antiparasitic patents (1988 - 2008).Recent Pat Antiinfect Drug Discov 2008;3:177-91
12. Gemma S, Travagli V, Savini L, et al.Malaria chemotherapy.Recent Pat Antiinfect Drug Discov 2010;5:195-225
13. Seven Indian patents published in English in 2010 - 2011 were not readily obtainable and hence excluded from this review 15.The Searete patents were excluded from this analysis 16.Muraleedharan KM, Avery MA.Progress in the development of peroxide-based anti-parasitic agents.Drug Discov Today 2009;14:793-803
14. Krishna S, Bustamante L, Haynes RK, et al.Artemisinins: their growing importance in medicine.Trends Pharmacol Sci 2008;29:520-7
15. Ding XC, Beck H-P, Raso G.Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets.Trends in Parasit 2011;27:73-81
16. The Johns Hopkins University.Preparation of trioxane monomer and dimer derivatives for use in the treatment of malaria and cancer.WO135427; 2010
17. The Johns Hopkins University.Preparation of trioxane dimer sulfur compounds useful in the treatment of cancer and malaria.WO009428; 2010
18. North-West University.Preparation of prodrugs of artemisinin as antimalarials.WO032165; 2010
19. Lombard MC, N'Da DN, Breytenbach JC, et al.Synthesis, in vitro antimalarial and cytotoxicity of artemisinin-aminoquinoline hybrids.Bioorg Med Chem Lett 2011;21:1683-6
20. Liverpool School of Tropical Medicine.Preparation of dispirocyclohexanyltetraoxanylcycloalkylphenol derivatives and analogs for use as antimalarials.WO109172; 2010
21. The Regents of the University of California.Fluorescent spiroadamantane-1,2,4-trioxolane derivatives as parasite cysteine protease inhibitors and their preparation, pharmaceutical compositions and use in the treatment of parasitic diseases and cancers.WO011684; 2010
22. The U.S.Army Medical Research and Material Command.Pentafluorosulfanyl analogs of mefloquine.WO144102; 2010
23. The U.S.Army Medical Research and Material Command.Next generation quinoloine methanols.WO144101; 2010
24. The U.S.Army Medical Research and Material Command.Derivatives of mefloquine and associated methods for making and using.WO144434; 2010
25. Milner E, McCalmont W, Bhonsle J, et al.Anti-malarial activity of a non-piperidine library of next generation quinoline methanols Malaria J.2010;9:51
26. Designmedix, Inc., Portland State University.Modified chloroquines with single ring moiety or fused ring moiety, their preparation and use for treating malaria.WO065932; 2010
27. Designmedix, Inc., Portland State University.Modified chloroquines with branched moiety.WO065925; 2010
28. Oregon Health & Science University, U.S.Department of Veterans Affairs.Aminoquinoline derivatives as antimalarial agents and their preparation, pharmaceutical compositions and their use in the treatment of parasitic diseases.WO059633; 2010
29. University of Cape Town.Preparation of quinoline compounds for treating malaria.WO018555; 2010
30. Actelion Pharmaceuticals.Novel bis-amides as antimalarial agents and their preparation and use in the treatment of protozoal infections.WO058353; 2010
31. Universita' Degli Studi Di Firenze, Istituto Superiore Di Sanita'.Preparation of 3-azabicyclo3.2.1.octane derivatives as peptidomimetic inhibitors of aspartyl-proteases for the treatment of infectious diseases.WO060904; 2010
32. Universita' Degli Studi Di Firenze, Istituto Superiore Di Sanita'.Preparation of 3-azabicyclo3.2.1.octane derivatives as peptidomimetic inhibitors of aspartyl-proteases for the treatment of infectious diseases.EP2189462; 2010
33. CSIR.Triazine derivatives for use in the treatment of malaria and their preparation.WO018742; 2011
34. Board of Regents University of Texas system, Monash University, Medicines for Malaria Venture.1,2,4-Triazolo[1,5- a]pyrimidine derivatives as dihydroorotate dehydrogenase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of malaria.WO041304; 2011
35. Board of Trustees of the University of Illinois.Preparation of alkynyl diphosphates as Enzyme inhibiting compounds and methods.WO044505; 2011
36. Andrews KT, Tran TN, Wheatley NC, Fairlie DP.Targeting histone deacetylase inhibitors for anti-malarial therapy.Curr Top Med Chem 2009;9:292-308
37. Georgia Tech Research Corp.Preparation of descladinose-clarithromycin- azithromycin non-peptide macrocyclic histone deacetylase (HDAC) inhibitors.US0197622; 2010
38. Sigma Tau Industrie Farmaceutiche Riunite S.p.A.Non-natural macrocyclic amides as HDAC6 inhibitors and their preparation and use in the treatment of diseases.WO047326; 2011
39. Elixir Pharmaceuticals, Inc.Compounds, compositions, and methods for treating malaria or leishmaniasis.WO054382; 2010
40. CNRS, Technische Universitat Carlowilhelmina Zu Braunchschweig. Preparation of new derivatives of thieno [2,3-b]pyridine and 5,6,7,8- tetrahydrothieno[2,3-b]quinoline useful in the treatment of malaria.WO042860; 2011
41. CNRS.Preparation of new derivatives of thieno[2,3-b]pyridine and 5,6,7,8- tetrahydrothieno[2,3-b]quinoline useful in the treatment of malaria.EP2308883; 2011
42. IRM LLC.Imidazopyrazinamine compounds as antimalarial agents and their preparation, compositions and use for the treatment of parasitic diseases.WO006143; 2011
43. Glaxo Group Ltd.Preparation of 4(1H)- pyridinone derivatives as antimalarial agents.EP2246329; 2010
44. Glaxo Group Ltd.Preparation of 4(1H)- pyridinone derivatives as antimalarial agents.WO081904; 2010
45. Glaxo Group Ltd.Preparation of 3-(2- phenylpyridin-5-yl)-4(1H)-pyridinone derivatives for use as antimalarial agents.WO142741; 2010
46. Yeates CL, Batchelor JF, Capon EC, et al.Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials.J Med Chem 2008;5:2845-52
47. Oregon Health & Science University, U.S.Department of Veterans Affairs.Preparation of naphthoquinones, acridones, quinolones, pyridones, anthraquinones, and xanthones as parasiticides.US7829578; 2010
48. Department of Health and Human Services as representative of the United States of America.Inhibitors of the plasmodial surface anion channel as antimalarials.WO011537; 2010
49. Eisai R&D Management Co., Ltd.Benzoxazole derivatives as toll-like receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of malaria.WO036908; 2010
50. Lexicon Pharmaceuticals, Inc.S1P receptor agonists for the treatment of cerebral malaria.WO051349; 2010
51. Lexicon Pharmaceuticals, Inc.Preparation of sphingosine-1-phosphate (S1P) lyase inhibitors for the treatment of cerebral malaria.US051353; 2010
52. Rheinische Friedrich-Wilhelms-Universtat Bonn.Pharmaceutical composition containing cannabinoid-receptor antagonists.WO045068; 2011
53. Rheinische Friedrich-Wilhelms-Universtat Bonn.Pharmaceutical composition containing cannabinoid-receptor 2 antagonists.EU2311443; 2011
54. Universita di Pisa.N-Hydroxyazole derivatives as lactate dehydrogenase inhibitors and their preparation and use for the treatment of diseases.WO054525; 2011
55. Emory University.Triarylmethane analogs and their use in treating cancers and other diseases.US0189762; 2010
56. Emory University.Use of imipramine blue and analogs in treating cancers and parasitic infections.WO0160296; 2010
57. Cempra Pharmaceuticals.Methods for treating malaria, tuberculosis and Mycobacterium Avium Complex (MAC) diseases using fluoroketolides.WO032052; 2011
58. Still JG, Schranz J, Degenhardt TP, et al.Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects.Antimicrob Agents Chemother 2011;55:1997-2003
59. Entarco SA.The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer.WO150100; 2010
60. Genesis Biopharma, Millenia Hope Biologics.Use of voacamine and related compounds to enhance the activity of existing malaria treatments.CA2655893; 2010
61. Radix Pharmaceuticals, Inc.Ocimum sanctum natural product derivatives with antimalarial activity.US0087469; 2010
62. Radix Pharmaceuticals, Inc.Small molecules with antiprotozoal activity.US292264; 2010
63. Immune Modulation, Inc.Derivatives of hypoestoxide and related compounds for treating malaria.WO056223; 2010
64. Immune Modulation, Inc.Derivatives of hypoestoxide and related compounds for treating malaria.US0120853; 2010
65. GSK Istrazivacki Centar Zagreb D.O.O.Preparation of 3'-N-substituted 9-deoxo- 9a-methyl-9a-aza-homo-erythromycin A having antimalarial activity.WO086351; 2010
66. Oregon Health & Science University, U.S.Department of Veterans Affairs.Preparation of quinolines and quinolones having antiparasitic or antiinfectious activity.WO65905; 2010
67. Genzyme Corp., Harvard, MIT.Preparation of 2-aminoindole compounds for the treatment of malaria.WO053697; 2011
68. University of Graz.Preparation of 3- azabicyclo3.2.2.nonane derivatives for treatment of malaria and trypanosomiasis.WO035355; 2011
69. University of Graz.Preparation of 3-azabicyclo3 2.2.nonane derivatives for treatment of malaria and trypanosomiasis.EP2301627; 2011
70. NIH.Compounds that treat malaria and prevent malaria transmission. WO022327; 2011
71. Sowunmi A.A randomised comparison of chloroquine and chloroquine plus ketotifen in the treatment of acute, uncomplicated, P.falciparum in children.Ann Trop Med Parasitol 2003;97:103-17
72. Anacor Pharmaceuticals, Inc.Boron-containing small molecules as antiprotozoal agents.WO025970; 2011
73. Anacor Pharmaceuticals, Inc.Boron-containing small molecules as anti-protozoal agents.WO045505; 2010
74. Anacor Pharmaceuticals, Inc.Boron-containing small molecules as anti-protozoal agents.WO045503; 2010
75. Zhang Y-K,, Plattner JJ, Freund YR, et al.Synthesis and structure-activity relationships of novel benzoxaboroles as a new class of antimalarial agents.Bioorg Med Chem Lett 2011;21:644-51
76. Available from: http://www.anacor.com/ pdf/Malaria-ASTMH-Poster-Final.pdf 80.4SC AG.Preparation of sulfamoylphenylureidobenzamidine derivatives for use as antimalarial agents.WO086177; 2010
77. The U.S.Army Medical Research and Material Command.Imidazolidinedione derivatives as antimalarial agents and their preparation, pharmaceutical compositions and use in the treatment of malaria.WO051129; 2010
78. University Health Network.Triazolium and imidazolium salts as parasiticides and their preparation, pharmaceutical compositions and use in the treatment of malaria.WO025558; 2010
79. Polymedix, Inc., The Trustees of the University of Pennsylvania. Preparation of aromatic and heteroaromatic compounds useful in the treatment of malaria.WO014573; 2010
80. Searete LLC.Anti-inflammatory compositions and methods for modulating Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.WO065118; 2010
81. Searete LLC.Anti-inflammatory compositions and methods for modulating Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.US0135983; 2010
82. Searete LLC.Anti-inflammatory compositions and methods for modulating Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.US0135984; 2010
83. Searete LLC.Anti-inflammatory compositions and methods for modulating Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.US0137247; 2010
84. Searete LLC.Anti-inflammatory compositions and methods for modulating Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.US0137844; 2010
85. Searete LLC.Anti-inflammatory compositions and methods for modulating Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.US0137246; 2010
86. Searete LLC.Anti-inflammatory compositions and methods for modulating Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.US0137843; 2010
87. Searete LLC.Anti-inflammatory compositions and methods for modulating Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.US0135908; 2010
88. Searete LLC.Anti-inflammatory compositions and methods for modulating Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.US0137787; 2010
89. Searete LLC.Anti-inflammatory compositions and methods for modulating Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.US0136097; 2010
90. Searete LLC.Anti-inflammatory compositions and methods for modulating Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.US0136096; 2010
91. Searete LLC.Anti-inflammatory compositions and methods for modulating Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.US0136095; 2010
92. Searete LLC.Anti-inflammatory compositions and methods for modulating Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.US0136094; 2010
93. Sun S, Rao NL, Venable J, et al.TLR7/9 Antagonists as therapeutics for immune-mediated inflammatory disorders.Inflamm Allerg Drug Targets 2007;6:223-5
94. Parroche P, Lauw FN, Goutagny N, et al.Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to toll-like receptor 9.Proc Natl Acad Sci USA 2007;104:1219-24
95. Searete LCC.Biological targeting compositions comprising red blood cells and methods of using.US00427072; 2010
96. Searete LCC.Biological targeting compositions and methods of using the same.US0040546; 2010
97. Advanced Applied Physics Solutions, Inc. Carbohydrate-metallocene- antimalarial conjugates.WO094130; 2010
98. University of Greenwich. Preparation of triazine compounds as sodium channel blockers.WO004196; 2011
99. University of Greenwich. Preparation of 1,2,4-triazine compounds as sodium channel blockers and as antimalarials.GB2471713; 2010
100. University of Greenwich. Preparation of 1,2,4-triazine compounds as sodium channel blockers and as antimalarials.GB2471729; 2010
101. Rees RWA, Russell PB, Foell TJ, Bright RE.Antimalarial activity of some 3,5-diamino-as-triazine derivatives.J Med Chem 1972;15:859-61
102. Albert Einstein college of Medicine of Yeshiva University.Transition state structure of orotate phosphoribosyltransferases and its uses to design antimalarial inhibitors.WO068239; 2010
103. IPCA Labarotories Ltd.Novel atovaquone-proguanil complex for treatment and/or prophylaxis of parasitic infections.WO021230; 2011
104. Bueno Calderon JM, Chicharro Gonzalo J, Lorenzo Garcia M, et al.Novel heterocyclic compounds.WO2007138048; 2007
105. Glaxogroup Ltd.Phosphate ester of a 4-pyridone derivative and its use in the chemotherapy of parasitic infections.WO094738; 2010
106. Citrox Ltd, Kimbolton, Cambridgeshire.Use of flavonoids to treat parasitic infection.EP2198862; 2010
107. National University of Singapore.Synthesis and use of coumarin fluorophore-tagged antimalarials.WO002415; 2011
108. Merck Frosst Canada Ltd.Preparation of dipeptide nitriles as papain family cysteine protease inhibitors for the treatment of parasitic diseases.WO148488; 2010
109. Cenix Bioscience GMBH, Faculdade de Mecidina Da Universidade de Lisboa.Use of inhibitors of host kinases for the treatment of infectious diseases.WO049172; 2010
110. Universitat de Sao Paolo, USP; Fundacao de Amparo A Pesquira Do Estado de Sao Paolo - FAPESP.Pharmaceutical composition, drug screening method and method for treating malaria.WO037198; 2010
111. Available from: http://www.gsk.com/ collaborations/our-commitment.htm
112. Available from: http://www.mmv.org/ research-development/ essentialinformation- scientists/target-productprofiles
113. Available from: http://www.mmv.org/ research-development/science- portfolio
114. Burrows JN, Chibale K, Wells TNC.The state of the art in anti-malarial drug discovery and development.Curr Top Med Chem 2011;11:1226-54
115. Wells TNC.Natural products as starting points for future anti-malarial therapies: going back to our roots? Malaria J 2011;10:S3: Available from: http://www.malariajournal.com/content/pdf/1475- 2875-10-S1-S3.pdf
116. Mboya-Okeyo T, Ridley RG, Nwaka S, et al.The African network for drugs and diagnostics innovation.Lancet 2009;373:1507-8